# EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX

> **NCT03126435** · PHASE3 · COMPLETED · sponsor: **SynCore Biotechnology Co., Ltd.** · enrollment: 218 (actual)

## Conditions studied

- Metastatic Pancreas Cancer
- Locally Advanced Pancreatic Cancer
- Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** EndoTAG-1
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT03126435
- **Lead sponsor:** SynCore Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-16
- **Primary completion:** 2021-07-30
- **Final completion:** 2021-10-08
- **Target enrollment:** 218 (ACTUAL)
- **Last updated:** 2023-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03126435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03126435, "EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03126435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*